Codman Neuro Acquires Neuravi
April 10, 2017—Codman Neuro announced the acquisition of Neuravi, a privately held Ireland-based company. DePuy Ireland Unlimited Company, an affiliate of Codman Neuro, is the acquiring entity. Financial terms of the transaction were not disclosed.
This transaction, which comes after the company's recent acquisition of Pulsar Vascular, complements Codman Neuro's comprehensive portfolio of products for hemorrhagic and ischemic stroke.
Neuravi's EmboTrap revascularization platform is designed to restore blood flow to the brain by retrieving a clot with the company's dual-layer stent-like structure. The EmboTrap and EmboTrap II revascularization devices are commercially available in Europe and have been available in the United States for investigational use only in the ARISE II clinical trial, which will support a US Food and Drug Administration submission planned for later this year. In February, Neuravi announced completion of patient enrollment in the pivotal ARISE II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) trial.